Drug Trial Radar · NCT07584226
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Mar 9, 2026
Primary completion
May 31, 2029
Study completion Jun 30, 2031
Sponsor
- Lead sponsor
- Relay Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma, colorectal and other solid tumors.
Conditions
- Advanced NRAS-Mutant Melanoma
- Advanced NRAS-Mutant Solid Tumors
- NRAS Mutation
- NRAS G12D
- NRAS G13R
- NRAS G13D
- NRAS G12V
- NRAS Q61R
- NRAS Q61K
- NRAS Q61L
- NRAS Q61H
- Advanced NRAS-mutant Colorectal Cancer
Interventions
RLY-8161Drug
RLY-8161 is an NRAS-selective inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Maximum Tolerated Dose (MTD) and/or RP2D of RLY-8161Time frame: Cycle 1 (28-day cycle) of treatment for MTD and at the end of every cycle (28-day cycle) for RP2D until treatment discontinuation, approximately 12 months
- Part 1: Number of participants with Adverse Events (AEs) or Serious Adverse Events (SAEs), with changes in vital signs, electrocardiograms (ECGs), and laboratory testsTime frame: Cycle 1 (28-day cycle) of treatment and at the end of every cycle (28-day cycle) until 30 days after treatment discontinuation, approximately 13 months
- Part 2: Objective Response Rate (ORR) of RLY-8161 as assessed by RECIST v1.1Time frame: Approximately every 8 weeks on treatment and every 12 weeks after last dose in the absence of progressive disease, approximately 18 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
University of Colorado Hospital
Aurora, Colorado · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
START Midwest, LLC
Grand Rapids, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Sarah Cannon Research Institute Oncology Partners
Nashville, Tennessee · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.